What We Do

Every morning, thousands of people in the UK wake up battling a hidden enemy: obesity. With a staggering one in three individuals grappling with this condition, the implications extend far beyond individual health. Obesity has woven itself into the very fabric of the UK health system, becoming a harbinger of chronic diseases like cardiovascular ailments and cancer. It’s not just personal; it’s societal, with an estimated cost of £11.4 billion annually to the NHS and an alarming £74.3 billion yearly due to associated ill health. These numbers are more than statistics; they are a clarion call for systemic change.

From Awareness to Action

In response to this escalating crisis, the UK Government launched the Obesity Healthcare Goals programme in November 2022, aimed at addressing these staggering statistics through innovation. As highlighted by Professor Naveed Sattar, Chair of the programme, “We are committed to transforming how we treat obesity, utilizing cutting-edge treatments and technologies to ensure long-term health outcomes for those affected.”

The first step in this ambitious initiative unfolded in 2023 with a competition through the National Institute for Health and Care Research. This competition aims to create a Phase 2 pre-licence platform designed to evaluate pharmaceutical and digital interventions that target obesity. The programme seeks to illuminate pathways toward more effective treatments, making the UK a testing ground for innovative health solutions.

One of the latest milestones came in October 2024, when the government inked a landmark agreement with Eli Lilly, the world’s largest pharmaceutical company. This partnership, involving a staggering £279 million investment, represents a cornerstone of the Obesity Healthcare Goals programme. “This collaboration allows the UK to become a key player in the global fight against obesity,” says Dr. Helen Mitchell, a prominent epidemiologist at the University of London. “We have a unique opportunity to trial innovative methods alongside established healthcare systems.”

Funding Innovative Solutions

But financial investments are just the tip of the iceberg. The UK is also spearheading initiatives like the Weight Management Pathway Design Accelerator through Innovate UK. This programme is set to invest up to £3 million in supporting NHS organizations to develop new, community-based models for patient access that are safe, effective, and resource-efficient.

“It’s crucial that we mobilize our systems for innovation, creating pathways that allow for quicker patient access to life sciences innovations,” says Professor Sattar. “This aligns perfectly with the objectives set forth by both the Department for Science, Innovation and Technology and the Department of Health and Social Care.”

Key Innovations in the Pipeline

• Pharmaceutical Interventions: New drugs aimed at appetite regulation and metabolism enhancement.
• Digital Solutions: Mobile applications enabling personalized health tracking and virtual consultations.
• Community-Based Models: Local initiatives focusing on preventive care and education to reduce obesity rates.

These developments don’t just promise a brighter future for patients living with obesity; they are also likely to influence healthcare efficacy across the board. Given the interconnectedness of health conditions, innovations aimed at tackling obesity could lead to improvements in managing other chronic diseases.

Who We Are

The voice driving the Obesity Healthcare Goals programme is none other than Professor Naveed Sattar, a figure celebrated not only for his extensive academic credentials but also for his dedication to redefining obesity research. As a Professor of Cardiometabolic Medicine at the University of Glasgow, and an Honorary Consultant at the Glasgow Royal Infirmary, Sattar embodies the confluence of clinical expertise and groundbreaking research.

“I see obesity as perhaps the major cause of multiple long-term conditions in the UK,” says Sattar. “Promoting the UK as a hub for obesity research is vital, given our superior health records and the wealth of academic talent available here.” His influential work over the past 25 years has shaped clinical practices across Europe, making him a world-leading authority in obesity and related conditions. With over 1,300 published papers to his name, Sattar remains in the top 1% of cited clinical academics globally, continually pushing the boundaries of conventional wisdom.

His commitment has not only garnered numerous prestigious awards but also significantly impacted national clinical guidelines, influencing how obesity is treated across different healthcare settings.

Further Information and Relevant Links

For those interested in joining the journey towards innovative obesity solutions, the Obesity Healthcare Goals programme is accessible via email: healthcaregoals@officeforlifesciences.gov.uk.

As the UK grapples with the challenges posed by obesity, we stand at a crossroads—a pivotal moment where concerted efforts from government, private sectors, and healthcare professionals can meld into a formidable response. With initiatives like the Obesity Healthcare Goals programme and the backing of world-class experts, we have an unprecedented opportunity to transform the narrative around obesity, making strides towards a healthier future for all.

Source: www.gov.uk